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Abstract
Context: Prader-Willi syndrome (PWS) is characterized by hypothalamic dysfunction, 
hyperphagia and a typical behavioural phenotype, with characteristics of autism spec-
trum disorder (ASD) like stubbornness, temper tantrums and compulsivity. It has been 
suggested that the oxytocin system in patients with PWS is dysfunctional. In ASD, 
intranasal oxytocin treatment has favourable effects on behaviour.
Objective: To evaluate the effects of 3 months of twice daily intranasal oxytocin (dose 
range 16-40 IU/day), compared to placebo, on behaviour and hyperphagia in children 
with PWS.
Design: Randomized, double-blind, placebo-controlled, crossover study in the Dutch 
PWS Reference Center.
Patients: Twenty-six children with PWS aged 3-11 years.
Main outcome measures: (Change in) behaviour and hyperphagia measured by 
Oxytocin Questionnaire and Dykens hyperphagia questionnaire.
Results: In the total group, no significant effects of oxytocin on social behaviour or 
hyperphagia were found. However, in boys, the Oxytocin Questionnaire scores im-
proved significantly during oxytocin treatment, compared to a deterioration during 
placebo (4.5 (−0.8 to 15.3) vs. −4.0 (−11.3 to 0.8), P = .025). The Dykens hyperphagia 
questionnaire scores remained similar during oxytocin treatment, while there was a 
deterioration during placebo (0.0 (−0.8 to 4.3) vs. −3.5 (−6.0 to 0.0), P = .046). Patients 
with a deletion had significant improvements in both questionnaire scores during 
oxytocin treatment, but deteriorations during placebo. Oxytocin treatment was well 
tolerated, and there were no serious adverse events.
Conclusions: Intranasal oxytocin treatment has positive effects on social and eating 
behaviour in 3-11 years aged boys with PWS and in children with a deletion without 
safety concerns. Intranasal oxytocin in children with PWS might be considered, but 
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1  |  INTRODUC TION
Prader-Willi syndrome (PWS) is a rare, neurodevelopmental disor-
der caused by the lack of expression of the Prader-Willi region of 
the paternally derived chromosome 15, mostly caused by a paternal 
deletion or maternal uniparental disomy (mUPD). PWS is character-
ized by a distinctive phenotype with neonatal hypotonia with suck-
ling problems often requiring tube feeding, endocrine disturbances, 
developmental delay, hyperphagia and reduced energy expenditure 
resulting in obesity when uncontrolled and a typical behavioural 
phenotype.1-3 Behaviour of children with PWS is characterized by 
stubbornness, temper tantrums, compulsivity and difficulties in 
changing routines.2,4,5 Children thereby show symptoms of autism 
spectrum disorder (ASD), and 36% fulfil the criteria of ASD.6 Growth 
hormone (GH) therapy results in significant improvements in body 
composition and mental and motor development in children with 
PWS.7,8 However, effects of GH on behaviour and hyperphagia are 
limited.9
One of the genes in the Prader-Willi region is Magel2. Magel2-
deficient mice have been shown to reproduce some of the pheno-
type of PWS.10,11 Magel2-deficient mice have a major reduction of 
hypothalamic oxytocin secretion and a 50% neonatal mortality due 
to suckling defects.10 A single oxytocin injection in mouse pups at 
3-5 hours after birth normalized suckling and feeding behaviour, re-
sulting in survival of all pups.10 Furthermore, in the 50% surviving 
adult mice, deficiencies in learning abilities and social behaviours 
were found.11 In these mice, oxytocin given 1 hour before be-
havioural testing reversed social recognition deficits.11 This might 
suggest that oxytocin could potentially influence at least some of 
the behavioural phenotypes of PWS. Furthermore, the number of 
oxytocin-expressing neurons in the hypothalamus of patients with 
PWS is significantly decreased12 and both higher and lower plasma 
oxytocin levels were found in PWS compared with healthy con-
trols.13,14 Altogether, findings suggest that the oxytocin system in 
patients with PWS is dysfunctional and oxytocin might be involved 
in the hyperphagia seen in PWS.
Oxytocin is known to be involved in social skills,15 food in-
take,16-18 energy expenditure19 and body weight,20 all of which are 
seriously affected in PWS. Currently, there are no pharmacother-
apeutic options to effectively reduce symptoms of hyperphagia. 
Most psychotropic options to alleviate severe behavioural prob-
lems have undesirable side effects. Studies of oxytocin in autism 
have shown favourable effects on behaviour.21-23 There are a few 
studies investigating short-term oxytocin, most for a maximum of 
4 weeks and one investigated 8 weeks of oxytocin, in both children 
and adults with PWS.24-29These studies show varying effects. Our 
previous randomized, double-blind, placebo-controlled, crossover 
trial investigating 4 weeks of oxytocin vs. placebo showed positive 
effects on social behaviour in children aged 6-11 years, but not 
in older children,28 indicating that younger children might benefit 
more from oxytocin treatment. However, there are currently no 
studies investigating effects of longer-term oxytocin treatment in 
young children with PWS.
Given the dysfunctional oxytocin system in PWS and involve-
ment of oxytocin in social skills, food intake and body weight, we 
hypothesized that intranasal oxytocin in young children with PWS 
would improve social behaviour and hyperphagia. We, therefore, 
conducted a randomized, double-blind, placebo-controlled cross-
over study on the effects of 3 months of oxytocin versus 3 months 
of placebo. The primary endpoints were changes in social behaviour 
and hyperphagia. Furthermore, we investigated if there was a dif-




Inclusion criteria were as follows: (a) genetically confirmed diagnosis 
of PWS; (b) age 3-11 years; (c) behavioural problems such as reduced 
social reciprocity, repetitive behaviour or temper tantrums, with or 
without hyperphagia defined as being in nutritional phase 2b or 3 
according to Miller30; and (d) using GH treatment for at least 1 year. 
Exclusion criteria were as follows: (a) severe psychiatric problems; (b) 
non-cooperative behaviour; (c) allergic reactions or hypersensitivity 
to oxytocin; (d) cardiac abnormalities; (e) extremely low dietary in-
take or less than minimal required intake according to WHO; and (f) 
using medication to reduce weight (fat).
Forty-six children with PWS were eligible. Parents of 3 children 
did not want to participate because they did not find their child's 
behaviour to be problematic, parents of 16 children did not want to 
participate due to too large a burden or practical issues concerning 
visits to study centre. One patient was scheduled to participate but 
had to withdraw due to scoliosis correction just before study start. 
The study group consisted of 26 children with PWS. All children 
were on GH therapy. Median daily GH dose was 0.67 mg/m2/day 
(~0.023 mg/kg/day).
The study protocol was approved by the Medical Ethics 
Committee of Erasmus University Medical Center, Rotterdam, The 
individual effects should be carefully evaluated and treatment discontinued if no ef-
fects are found.
K E Y W O R D S
behaviour, children, hyperphagia, intranasal oxytocin, Prader-Willi syndrome
    |  3DAMEN Et Al
Netherlands. Written informed consent was obtained from parents 
and assent was obtained from children.
2.2  |  Design
Randomized, double-blind, placebo-controlled, crossover design 
was used to investigate effects of intranasal oxytocin on social 
behaviour and food intake. Children received either oxytocin or 
placebo for 3 months, followed by a 1-month wash-out period. 
Following the wash-out period, patients crossed over to the alterna-
tive treatment for a further 3 months. An independent statistician 
generated the random allocation sequence, and only the statisti-
cian and independent pharmacist were unblinded. Because of pos-
sible age and sex effects, children were stratified according to age 
(3-6.99 years and 7-10.99 years) and sex, and then randomly and 
blindly assigned to receive twice daily, before breakfast and din-
ner, intranasal administration of either oxytocin (Syntocinon®, 2 IU/
puff, Defiante Farmaceutica Portugal) or identical appearing placebo 
(placebo, 0 IU/puff, UniversitätsKlinikum Heidelberg Apotheke, 
Germany). Placebo consisted of aqua conservans, sodium chloride, 
chlorobutanol and glycerine. Both oxytocin and placebo nasal sprays 
were packaged and labelled by the UniversitätsKlinikum Heidelberg 
Apotheke, Germany. Nasal spray bottles were collected at the end 
of a study phase and it was recorded if they were empty or full at the 
end of a study phase. Compliance was assessed at the study visits by 
asking about missed doses. Dose was based on doses used in other 
trials15,26,28 and calculated according to body surface area; <0.8 m2 
b.i.d. 8IU; 0.8-1.15 m2 b.i.d. 12IU; 1.15-1.45 m2 b.i.d. 16IU; and 1.45-
1.75 m2 b.i.d. 20IU.
2.3  |  Measurements
Children were examined at the outpatient clinic four times during 
the study: baseline visit before start of nasal spray (Visit 1); after 
3 months, end of first phase (Visit 2); after 4 months, end of wash-
out period (Visit 3); and after 7 months, end of second phase (Visit 
4). Standing height was measured with a calibrated Harpenden sta-
diometer and weight on a calibrated scale (Servo Balance). Height, 
weight and body mass index (BMI) standard deviation scores (SDS) 
were calculated with Growth Analyser 4.0 (available at www.growt 
hanal yser.org) and were adjusted for sex and age according to Dutch 
reference values.31,32 DXA (Lunar Prodigy; GE Healthcare) was used 
to measure fat percentage. All scans were made on the same ma-
chine with daily quality assurance.
Fasting glucose and insulin were collected after an overnight 
fast and assayed in the Biochemical and Endocrine laboratories of 
Erasmus Medical Center, Rotterdam. The last dose of oxytocin/
placebo nasal spray was given the evening before collection. Blood 
samples for acylated ghrelin (AG) and unacylated ghrelin (UAG) 
were collected in EDTA tubes, and 4-(2-aminoethyl)benzenesulpho-
nyl fluoride hydrochloride (AEBSF, Sigma-Aldrich Chemicals) was 
added to a concentration of 2 mg/ml at time of collection. Blood 
was centrifuged at 4℃ to prepare plasma, which was quickly frozen 
and stored at −80℃ until assayed. Assays were performed as de-
scribed previously.33 Samples with an extremely low AG/UAG level 
(<0.1) were excluded due to stabilization concerns. Oxytocin levels 
in blood samples were measured in duplicate with an oxytocin ELISA 
kit (Enzo Life Sciences).
2.4  |  Recording of safety and adverse events
The first nasal spray of each phase was administered at the study 
centre. Patients were observed after administration for 60 minutes 
with a standard checklist for possible adverse events (eg nausea, 
skin rash). Furthermore, blood pressure and oxygen saturation were 
measured before administration of the nasal spray, and ten and 
60 minutes thereafter. No adverse effects occurred during obser-
vation. After the observation, patients were allowed to leave the 
study centre and parents were carefully instructed to call our special 
study mobile phone 24/7 in case they had any concerns regarding 
adverse effects. Adverse events were assessed during the study vis-
its. Furthermore, 4 weeks after the start of a nasal spray parents 
were contacted by phone for evaluation of possible adverse effects.
2.5  |  Questionnaires
Parents completed questionnaires at all visits. Parents completed 
Oxytocin Questionnaire28 and Dykens Hyperphagia Questionnaire 
measuring changes in eating behaviour.34 Oxytocin Questionnaire 
unravels changes in emotions and social and eating behaviour, and 
was also used in our previous study.28 Parents were asked to score the 
change from −3 (much less frequently) to +3 (much more frequently) 
and a positive score represented an improvement. Furthermore, par-
ents were asked to complete the Repetitive Behavior Scale-Revised 
(RBS-R)35-37 and Social Responsiveness Scale (SRS-P).38
Parents also completed standardized diaries about behaviour 
during 5 days prior to a visit. In the behavioural diary, parents were 
asked to record the number of events (eg temper tantrums or happy 
episodes) happening during a day.
2.6  |  Statistics
Castor EDC was used for data capture.39 Statistical analyses were 
performed with SPSS version 24.0 (SPSS Inc, Chicago, IL). For cal-
culating sample size, SD and effect size were based on a previous 
study in young children with autism using SRS-P.23 We used the 
standard deviation of the difference between two values for the 
same patient of 17 and minimal detectable difference of 10. Power 
was set at 0.8 and significance level of 0.05. Based on these val-
ues, a total of 25 patients had to enter the two-treatment crosso-
ver study. To avoid carry-over effects between phases 1 and 2, a 
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wash-out period was implemented. Statistical analyses appropri-
ate for crossover trials were used, taking into account any carry-
over or period effect, but these were not found. Results after 
3 months of either oxytocin or placebo were primary outcome 
measures. Results of visits (ie questions about changes or total 
score on questionnaire) or differences (Δ) between visits 1 and 
2, and between visits 3 and 4 were assessed. Effect of oxytocin 
versus placebo was tested by paired sample t-test or Wilcoxon 
tests, in case of continuous data and McNemar tests in case of 
binary data. Primary endpoint was the effect of oxytocin on so-
cial behaviour assessed by the Dykens Questionnaire, Oxytocin 
Study Questionnaire, SRS-P and RBS-R. Because of possible age, 
sex or genotype effects, we investigated correlations between age 
and effects and performed subanalyses in boys vs. girls and dele-
tion vs. mUPD. Results were considered significant if P-value was 
<0.05.
3  |  RESULTS
3.1  |  Baseline Characteristics
No carry-over or period effect was found. Table 1 shows baseline 
characteristics of 26 children with PWS who were included between 
May 2018 and May 2019. Median age at inclusion was 7.5 (5.6-9.1) 
years, and BMI was 1.8 (0.3-3.5) SDS. Fourteen (53.8%) patients had 
TA B L E  2  Effects on hyperphagia and social behaviour of total group
Items investigated
After 12 weeks of oxytocin After 12 weeks of placebo
P*Median IQR Median IQR
Oxytocin study 
questionnaireb 
Total score 1.0 (−5.5 to 11.0) -2.0 (−8.5 to 5.5) 0.20
Better Same Worse Better Same Worse
Total score 13 3 9 8 3 14 0.30
Happiness 10 15 0 5 19 1 0.27
Anxious 6 17 2 1 22 2 0.06
Food seeking behaviour 5 18 2 0 21 4 0.06
Dykens change in 
hyperphagiab 
Total score 0.0 (−1.0 to 3.0) 0.0 (−6.0 to 0.0) 0.06
Better Same Worse Better Same







RBS-R total scorea  11.0 (5.5-16.5) 14.0 (5.0-22.5) 0.20
SRS-P total scorea  68.0 (55.0-80.5) 68.0 (50.0-78.5) 0.52
Measurements
∆weight (kg) 1.0 (0.4-2.1) 1.0 (0.6-1.4) 0.70
∆BMI (kg/m2) 0.3 (−0.3 to 0.7) 0.3 (−0.1 to 0.6) 0.65
∆fat percentage 0.3 (−1.0 to 1.4) 0.3 (−0.9 to 1.7) 0.59
∆lean body mass (gram) 552.0 (115.8-913.0) 357.5 (−315.5 to 869.5) 0.21
Safety
Systolic blood pressure 105.0 (100.0-112.0) 108.0 (97.8-116.3) 0.55
Diastolic blood pressure 66.0 (61.0-69.0) 65.0 (57.0-76.5) 0.87
Fasting glucose 5.0 (4.6-5.1) 4.8 (4.5-5.1) 0.08
Fasting insulin 58.0 (41.0-101.8) 64.5 (26.0-92.0) 0.90
Note: Data expressed in median (IQR) unless otherwise specified;
ba positive score indicates improvement. 
aa higher score indicates more problems in behaviour. 
*P-value between oxytocin and placebo phase. P-value for variables expressed in better, same, worse, is the P-value for better versus same and 
worse. 
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a deletion and twelve (46.2%) an mUPD. Weight for height SDS and 
BMI SDS were significantly higher in patients who received oxytocin 
in the first study phase, than in those who received oxytocin in the 
second study phase. Other characteristics did not differ. There were 
no differences between boys and girls at study start. One patient 
dropped out during the second study phase, while receiving oxy-
tocin, due to serious family health problems. Results from this pa-
tient were not used in analyses.
3.2  |  Effects of oxytocin on social behaviour and 
food behaviour
3.2.1  |  Total group
Table 2 shows questionnaire results after 3 months of oxytocin 
or placebo. Median (IQR) Oxytocin Questionnaire score was 1.0 
(−5.5 to 11.0) after oxytocin and −2.0 (−8.5 to5.5) after placebo, 
(P = .20), with positive scores reflecting improvement in behav-
iour and negative scores reflecting deterioration. Change in hy-
perphagia measured by Dykens questionnaire showed a trend to 
being less hyperphagic after oxytocin (P = .06). Total score (IQR) 
on RBS-R was 11.0 (5.5-16.5) after oxytocin and 14.0 (5.0-22.5) 
after placebo (P = .20), with lower scores reflecting less repetitive 
behaviour. There was no difference in total score on SRS-P be-
tween oxytocin and placebo. Fourteen parents reported improve-
ment in social behaviour of their child during oxytocin, while six 
reported improvement during placebo, indicating a trend (P = .12). 
Seven parents reported improvement in eating behaviour during 
oxytocin versus one during placebo, indicating a trend (P = .07). 
Fourteen parents were able to correctly tell in which phase their 
child received oxytocin, while five thought their child was re-
ceiving oxytocin when their child was in fact receiving placebo. 
Children of the latter five parents were all <6 years. Parents in 
the older age group either did experience positive effects during 
oxytocin (N = 9) or did not experience a difference (N = 5). Parents 
were given the option to continue open-label oxytocin nasal spray. 
Fifteen (57.7%) parents chose to continue open-label oxytocin be-
cause they felt that their child had experienced substantial ben-
eficial effects.
In the diary about behaviour, parents reported a trend to more 
positive behaviour during oxytocin compared to placebo (P = .06) 
and reported a trend to fewer episodes of self-injurious behaviour 
during oxytocin compared to placebo (P = .09). There was no differ-
ence in reported temper tantrums or conflicts during oxytocin vs. 
placebo.
3.2.2  |  Sex-dependent effects of 
oxytocin treatment
We anticipated, before study start, that there might be a differ-
ence in oxytocin effects between boys and girls, and patients were, 
therefore, stratified according to sex. Indeed, our results showed a 
difference in effects between boys and girls (Table 3).
In boys, median (IQR) Oxytocin Questionnaire score after oxyto-
cin was 4.5 (−0.8 to 15.3), indicating improvement, while it was −4.0 
(−11.3 to 0.8) after placebo, indicating deterioration of behaviour, 
which was a significant difference (P = .025). After 3 months of oxy-
tocin, change in Dykens hyperphagia score was 0.0 (−0.8 to 4.3), 
while placebo resulted in a worsening of hyperphagia of −3.5 (−6.0 
to 0.0) (P = .046).
In girls, there were no significant differences between oxytocin 
or placebo in any of the questionnaires.
3.2.3  |  Effects in genetic subtypes
We next investigated if there was a difference in effects of oxytocin 
between patients with a deletion or mUPD (Table 4).
In patients with a deletion, Oxytocin Questionnaire score signifi-
cantly improved during oxytocin (5.5 (−0.3 to 15.0)), compared to 
deterioration (−1.5 (−12.8 to 3.0)) during placebo (P = .03). Dykens 
hyperphagia questionnaire score also significantly improved during 
oxytocin, compared to placebo (P = .03).
In boys with a deletion, although this group was small, there was 
a significant difference between oxytocin and placebo in Oxytocin 
Questionnaire scores, being 9.0 (0.0-18.0) after oxytocin versus −2.0 
(−12.0 to 0.0) after placebo (P = .04). Change in the Dykens hyper-
phagia score showed a trend, being 0.0 (0.0-2.0) after oxytocin ver-
sus −6.0 (−6.5 to 0.0) after placebo (P = .08).
In patients with an mUPD, no differences were found between 
oxytocin and placebo.
3.2.4  |  Effects of oxytocin on other parameters 
in the total group
There was no difference between oxytocin and placebo in ∆weight, 
∆BMI or ∆fat percentage after 3 months. During oxytocin, AG had 
a median decrease of −10.6 (−88.1 to 34.2) pg/ml, while during pla-
cebo, there was an increase of 17.4 (−53.6 to 47.9) pg/ml, but this 
difference was not significant (P = .27) (Table 5). UAG increased 
during both oxytocin and placebo. AG/UAG ratio decreased during 
oxytocin, while remaining similar during placebo, however this dif-
ference did not reach statistical significance in the eleven subjects 
available for analyses (P = .25). There was a higher increase in serum 
oxytocin levels during oxytocin than during placebo, but not signifi-
cant (786 (−168 to 2896) pg/l and 363 (−475 to 1775) pg/l, respec-
tively P = .27).
3.2.5  |  Safety parameters
Intranasal administration of oxytocin was well tolerated. Compliance 
was remarkably high, and only few parents reported to occasionally 
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have missed a dose (eg on a day out during the weekend). There was 
one serious adverse event during the study: one patient developed 
gastroparesis while receiving placebo, probably caused by an infection 
for which hospitalization was required. This patient recovered without 
sequelae. Five patients reported headache, four during placebo and 
one during oxytocin. Nasal irritation was reported by three patients, 
two during placebo and one during oxytocin. One patient reported a 
skin rash during placebo. There was no difference in blood pressure 
and fasting glucose or insulin levels between oxytocin and placebo.
3.2.6  |  Applicability of questionnaires
We noticed that the four questionnaires showed conflicting results in 
some children, as one questionnaire could indicate an improvement in 
behaviour, while another questionnaire indicated a deterioration. To 
assess if questionnaires adequately reflected the subjective feeling of 
parents, that there was an improvement in behaviour during one study 
phase, we investigated the scores of questionnaires completed by 
parents who felt there was a difference in behaviour between the two 
phases. In the fourteen parents who correctly pointed out in which 
phase their child received oxytocin, Oxytocin Questionnaire showed 
significant improvement in behaviour during oxytocin compared to 
placebo, with score of 8.5 (3.8-16.5) after oxytocin and −6.5 (−15.5 
to 2.3) after placebo (P < .001). Dykens questionnaire also showed 
significant improvement during oxytocin compared to placebo, with a 
score of 2.0 (−0.3 to 5.0) vs. −3.0 (−6.3 to 0.0), resp. (P = .007). RBS-R 
and SRS-R did not show significant differences in scores between 
oxytocin and placebo. In the five parents who thought their child re-
ceived oxytocin, while in fact receiving placebo, there was a trend for 
the Oxytocin Questionnaire score to favour placebo over oxytocin, 
with a score of 10.0 (−3.5 to 15.5) after placebo and −11.0 (−17.0 to 
−4.5) after oxytocin (P = .07), while there was no difference between 
the two phases regarding the other questionnaires.
4  |  DISCUSSION
Our current randomized, double-blind, placebo-controlled, cross-
over study is the first study to investigate effects of 3 months of 
oxytocin in children with PWS aged 3-11 years. In the total group, 
there were no significant differences between oxytocin and pla-
cebo, although more parents reported improvement in social and 
eating behaviour during oxytocin than during placebo. However, 
when analysed separately, boys showed significant positive effects 
of oxytocin on hyperphagia, and social and eating behaviour. In girls, 
no significant beneficial effects were found. Patients with a deletion 
had significant positive effects, but patients with an mUPD did not.
In the current study, oxytocin treatment had a positive (suppres-
sive) effect on hyperphagia in boys and in patients with a deletion, 
and there was a trend to a positive effect in the total group. When 
looking at the scores of Dykens questionnaire, it seems that oxy-
tocin prevents worsening of hyperphagia, since score was 0 during 
oxytocin and negative during placebo. This might be explained by 
the age range during which hyperphagia becomes more prominent 
according to Miller.30 Oxytocin might thus be able to prevent pro-
gression to higher nutritional phases.
There are currently a few studies describing the effects of short-
term oxytocin nasal spray in children with PWS.29 Our previous 
randomized, placebo-controlled, crossover study found positive ef-
fects of 4 weeks of oxytocin nasal spray versus placebo on social 
behaviour and hyperphagia in children aged 6-11 years,28 suggest-
ing that younger children might benefit more from oxytocin. We, 
therefore, included children aged 3-11 years in the current study. 
We could not confirm an age association, which might be due to the 
less problematic behaviour in very young children, which cannot be 
detected by questionnaires. Alternatively, there may be no age as-
sociation <11 years.
Most studies investigating effects of oxytocin in PWS have re-
ported some potential effects of oxytocin, but no study has shown 
convincing evidence for beneficial effects.25-29,40 This is probably 
caused by the nature of the studied outcomes, being behaviour, and 
the fact that they are assessed by questionnaires. There are currently 
no questionnaires assessing the specific behavioural type seen in 
PWS. We, therefore, chose to use questionnaires often used in ASD, 
since children with PWS show symptoms of ASD.6 However, these 
questionnaires probably do not fully capture the specific behavioural 
type seen in PWS. Furthermore, the four questionnaires used in our 
study sometimes resulted in conflicting outcomes in one child. We 
tried to investigate which questionnaire best reflected the subjective 
TA B L E  5  Other parameters
Items investigated
After 12 weeks of oxytocin After 12 weeks of placebo
P*Median IQR Median IQR
∆AG (pg/ml)a  (N = 12) -10.6 (−88.1 to 34.2) 17.4 (−53.6 to 47.9) 0.27
∆UAG (pg/ml)a  (N = 11) 13.0 (−34.6 to 32.8) 12.7 (−123.2 to 95.3) 0.42
∆AG/UAG ratio (pg/ml)a  (N = 11) -0.14 (−0.52 to 0.26) 0.0 (−0.29 to 0.63) 0.25
Oxytocin in serum (pg/ml) 
(N = 13)
4106 (3065-8027) 4264 (3371-6381) 0.31
∆ Oxytocin in serum (pg/ml) 786 (−168 to 2896) 363 (−475 to 1775) 0.27
aa positive score indicates a higher AG or UAG or AG/UAG ratio at the end of the OX/PL period. 
* P-value between oxytocin and placebo phase. 
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feelings of parents regarding behaviour. Oxytocin Questionnaire and 
Dykens hyperphagia questionnaire showed significant improvements 
during oxytocin when parents reported improvements in (eating) be-
haviour during oxytocin, while RBS-R and especially SRS-P did not. 
During this study, we found that the SRS-P questionnaire was not 
suitable for our study population and we therefore did not analyse 
this questionnaire further in subanalyses. Due to a lack of validated 
behaviour questionnaires for PWS, it will remain hard to find objec-
tive evidence for interventions. Even trends to improvements on 
currently available questionnaires might, therefore, be an important 
indication that an intervention such as oxytocin influences behaviour.
In the current study, we found positive effects of oxytocin in 
boys, but not in girls. This difference between boys and girls has not 
been described.25-28 There are some possible explanations for this 
observed sex difference. First, effects of oxytocin were measured 
by questionnaires. It is possible that the problematic behaviour 
measured by these questionnaires is better captured in boys than in 
girls. Second, it could be that there is a difference in oxytocin system 
between boys and girls, making boys more sensitive to oxytocin ef-
fects. A study in young children with ASD showed positive effects 
of oxytocin on social and repetitive behaviour. In that study, how-
ever, 87.1% of participants were male, which might explain why they 
found significant differences between oxytocin and placebo.23 Also, 
other studies in ASD showing positive effects of oxytocin investi-
gated mainly or only males.21,22,41 Future studies should investigate 
this sex-dependent difference in oxytocin effects in more detail.
We also found that patients with a deletion had significant ben-
eficial effects of oxytocin compared to placebo, while patients with 
an mUPD did not. This is in contrast to what we expected, since 
there is a higher prevalence of ASD in patients with an mUPD than 
in patients with a deletion.6,42 However, other studies reported that 
the deletion subtype might be associated with more maladaptive be-
haviour, more skin-picking and more overeating,43,44 all symptoms 
on which oxytocin might have positive effects. Previous studies ei-
ther did not find differences between genetic subtype28 or did not 
investigate if there was a difference.5,27 However, a study by Tauber 
et al found that after a single intranasal administration of oxytocin, 
there was an increased trust in others, decreased sadness tenden-
cies with less disruptive behaviour in the two days following admin-
istration and the majority of that study population (79%) consisted 
of patients with a deletion.25
We found a decrease in AG during oxytocin and an increase in 
AG during placebo, while UAG increased during both oxytocin and 
placebo, resulting in a lower AG/UAG ratio after oxytocin and a sta-
ble AG/UAG ratio after placebo. A lower AG/UAG ratio suggests a 
decrease in orexigenic drive. Although differences between oxyto-
cin and placebo were not significant, there seems to be a trend. We 
showed previously that children with PWS had a higher AG/UAG 
ratio than healthy controls and that the switch to excessive weight 
gain in PWS seemed to coincide with an increase in AG/UAG ratio.33 
Although non-significant, the decrease in AG/UAG ratio during oxy-
tocin could be the underlying mechanism explaining the effect of 
oxytocin on eating behaviour.
Oxytocin treatment was very well tolerated and no serious 
adverse events were reported, indicating that oxytocin treatment 
during 3 months is safe. Compliance was high. However, before defi-
nite conclusions can be drawn, studies are needed to investigate 
long-term safety.
Altogether, it appears that oxytocin has beneficial effects in 
some, but not all patients with PWS. It is important for future studies 
to investigate which patients might benefit from oxytocin treatment 
and confirm our findings. Furthermore, it could be that intranasal 
oxytocin has different effects at different ages. A study in infants 
with PWS aged <6 months showed positive effects of a short course 
of oxytocin on feeding and social skills.24 Furthermore, these oxyto-
cin-treated children displayed higher social skills at a median age of 
26.5 months and were more engaged in relationships than children 
of comparable age who did not receive early oxytocin.24
The strength of current study is the placebo-controlled, dou-
ble-blind, crossover design with a duration of 3 months. Furthermore, 
there was a high compliance during the study. A limitation of current 
study is the small sample size, particularly in the subanalyses, al-
though a total sample size of 25 is relatively large for a rare disorder 
like PWS. Another limitation is the suboptimal questionnaires avail-
able for patients with PWS to identify changes in eating and social 
behaviour.
In conclusion, intranasal oxytocin treatment has positive effects 
on social and eating behaviour in boys with PWS and in those with 
a deletion. It is difficult to objectively measure effects of intranasal 
oxytocin treatment on social behaviour, but more parents reported 
an improvement in social and eating behaviour during oxytocin than 
during placebo and more than half of the parents wanted their child 
to continue off-label oxytocin treatment because of this. These pos-
itive effects have the potential to significantly improve quality of life 
of the children and their families. Intranasal oxytocin treatment in 
children with PWS might be considered, but on individual basis as 
the positive effects are quite variable among children with PWS. 
Therefore, effects should be evaluated and treatment discontinued 
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